Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 202Recurrence 53Neoplasms, Plasma Cell 19Neoplasms 13Immunoglobulin Light-chain Amyloidosis 10Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Myeloproliferative Disorders 4Lymphoma, B-Cell 4Hematologic Diseases 4Amyloidosis 4Waldenstrom Macroglobulinemia 3Sarcoma, Kaposi 3Renal Insufficiency 3Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, Follicular 2Disease Progression 2Chromosome 17 deletion 2Central Nervous System Neoplasms 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1

Interventions

Cyclophosphamide 193fludarabine phosphate 123Peripheral Blood Stem Cell Transplantation 107Etoposide 106Mycophenolic Acid 95Filgrastim 92Doxorubicin 85Whole-Body Irradiation 84Tacrolimus 81Brentuximab Vedotin 80Melphalan 78Busulfan 75Radiotherapy 74fludarabine 68Cyclosporine 67Vinblastine 65Rituximab 60Dacarbazine 56Granulocyte Colony-Stimulating Factor 53Gemcitabine 52Antilymphocyte Serum 51Bleomycin 50Nivolumab 47Methotrexate 47Vincristine 46Prednisone 45Cytarabine 44pembrolizumab 36Carmustine 36Bendamustine Hydrochloride 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × pomalidomide × Clear all
NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡